RxDoctor Payments DataLook up a doctor →

Ashish Sadhu, MD

Clinical Cardiac Electrophysiology · Scottsdale, AZNPI 1124218607

Payments from drug & device makers

$1,309,051in general payments, 2019–2025

Across 1,016 payments — averaging $1288.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1.3M
  • Abbott$34K
  • Medtronic$14K
  • Biotronik Inc.$2K
  • Biosense Webster, Inc.$2K
  • Novartis$1K
  • plus $4K from 38 others

What the payments were for

  • Consulting fees$65,68125%
  • Speaking & faculty fees$146,48855%
  • Grants$1,7371%
  • Travel & lodging$15,1916%
  • Food & beverage$35,31013%
  • Education$580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,309,051 in reported general payments places this provider in the 95th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

See all clinical cardiac electrophysiology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,180,085
Medicare patients
1,479
Services billed
14,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban350$376,861
EntrestoSacubitril/Valsartan45$72,621
XareltoRivaroxaban74$69,140
MultaqDronedarone Hcl15$30,529
JardianceEmpagliflozin21$24,699
Dofetilide68$16,647
Repatha SureclickEvolocumab12$6,407
Metoprolol Succinate172$2,782
SotalolSotalol Hcl116$2,714
Amiodarone Hcl28$2,178
Diltiazem 24hr Er (Cd)Diltiazem Hcl62$1,856
Flecainide Acetate43$1,695
Atorvastatin Calcium130$1,151
Diltiazem Hcl26$944
Metoprolol Tartrate66$850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$350$376,861350 claims
NovartisEntresto$1,085$72,62145 claims
Johnson & JohnsonXarelto$54$69,14074 claims
Sanofi-aventis U.S. LLCMultaq$50$30,52915 claims
Boehringer IngelheimJardiance$49$24,69921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

Other clinical cardiac electrophysiology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →